Provided herein are compositions comprising a Clostridium botulinum neurotoxin serotype A (BoNT/A) complex comprising a 150 kDa BoNT/A. Said 150 kDa BoNT/A is in the form of a plurality of sequence variant species, wherein the plurality of sequence variant species comprises a 150 kDa BoNT/A sequence variant species with a C-terminal truncated light chain.
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
ABBVIE INC. (USA)
Inventor
Alexanian, Erik
Gruhin, Jonathan
Kim, Richard
Leibfarth, Frank
Voight, Eric A.
Abstract
The subject matter contained herein relates generally to methods for the radical-mediated introduction of the acyl phosphonate group via use of a radical-polar conjunctive reagent. In certain embodiments, the methods provide direct one carbon homologation of carboxylic acids to diverse carbonyl compounds via acyl phosphonates. In certain embodiments, the methods provide introduction of the acyl phosphonate group via the C–H functionalization of small molecules and polyolefins. The subject matter described herein provides the ability to efficiently and selectively insert the acyl phosphonate group to diverse hydrocarbon substrates ranging from small molecules to polymers with >3500 carbon atoms. The ability to both perform direct one carbon homologations of carboxylic acids and to introduce the acyl phosphonate as a diversifiable moiety via C–H functionalization holds significant promise in both medicinal and synthetic chemistry.
The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Provided herein are compounds of Formula (I), compounds of Formula (II) and pharmaceutically acceptable salts thereof, useful as LPAR1 inhibitors, and pharmaceutical compositions comprising the same. Also provided are methods of treating or preventing a disease or condition comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (II).
Provided herein are compounds of Formula (I), compounds of Formula (II) and pharmaceutically acceptable salts thereof, useful as LPAR1 inhibitors, and pharmaceutical compositions comprising the same. Also provided are methods of treating or preventing a disease or condition comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (II).
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
Provided are methods for treating various spondyloarthritic and psoriatic conditions, including types of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis (PsO), with the JAK1 inhibitor, upadacitinib free base or pharmaceutically acceptable salt thereof. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA), methods for treating active ankylosing spondylitis (AS), methods for treating active psoriatic arthritis (PsA), and methods for treating active psoriasis (PsO).
Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Prescription-only pharmaceutical preparations and substances for the treatment of neurological diseases and disorders Providing medical information in the field of neuroscience and psychiatry, including neurological diseases and disorders
The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
The present invention relates to dosing regimens for GnRH receptor antagonists, and, in particular, dosing regimens for 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof, in subjects suffering from, for example, endometriosis, adenomyosis, polycystic ovary syndrome (PCOS), or uterine fibroids, to minimize changes in bone mineral density associated with such GnRH receptor antagonists.
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
The present disclosure provides dual variable domain immunoglobulin (DVD-Ig) molecules that bind to human STEAP1 and human PSMA and their drug conjugates, and methods of using the same.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
23.
TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIB
Provided is the JAKI inhibitor upadacitinib free base or a pharmaceutically acceptable salt thereof for use in methods for treating various spondyloarthritic and psoriatic conditions, including types of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis (PsO). In various aspects, upadacitinib free base or a pharmaceutically acceptable salt thereof is for use in methods for treating active non-radiographic axSpA (nr-axSpA), methods for treating active ankylosing spondylitis (AS), methods for treating active psoriatic arthritis (PsA), and methods for treating active psoriasis (PsO).
Provided is the JAKI inhibitor upadacitinib free base or a pharmaceutically acceptable salt thereof for use in methods for treating various spondyloarthritic and psoriatic conditions, including types of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis (PsO). In various aspects, upadacitinib free base or a pharmaceutically acceptable salt thereof is for use in methods for treating active non-radiographic axSpA (nr-axSpA), methods for treating active ankylosing spondylitis (AS), methods for treating active psoriatic arthritis (PsA), and methods for treating active psoriasis (PsO).
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of dermatological, musculoskeletal, rheumatological, gastroenterological, inflammatory, and immune system related diseases and disorders
The present disclosure provides anti-α4β7 antibodies that bind human α4β7, their methods of making, and their uses to treat patients with HIV infection.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
49.
ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS
Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
50.
METHODS OF TREATING PANCREATIC TUMORS EXPRESSING CERTAIN BIOMARKERS
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals for human use, namely, pharmaceutical preparations for treatment of cancer; pharmaceuticals for human use, namely, pharmaceutical preparations for treatment of oncological diseases, disorders, and conditions
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals for human use, namely, pharmaceutical preparations for treatment of cancer; pharmaceuticals for human use, namely, pharmaceutical preparations for treatment of oncological diseases, disorders, and conditions
The present invention provides for compounds of Formula (I)
The present invention provides for compounds of Formula (I)
The present invention provides for compounds of Formula (I)
wherein A, L, W, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SLL, and/or ALL.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.
The disclosure describes extended release solid dosage forms comprising upadacitinib, or a pharmaceutically acceptable salt thereof, wherein the solid dosage form provides pH-independent drug release. In particular, the disclosure describes extended release solid dosage forms comprising upadacitinib, or a pharmaceutically acceptable salt thereof, at least one pH-dependent polymer and at least one release control material.
Drug delivery reservoir for delivery of a beneficial agent to a user includes a drug delivery reservoir housing having a fluid reservoir defined therein. The drug delivery reservoir housing has a drug delivery reservoir base region. The drug delivery reservoir includes a dip tube extending inside the fluid reservoir. The dip tube includes a tubular wall defining a flow lumen. The tubular wall has at least one aperture defined therein and spaced proximally from a distal end of the tubular wall in fluid communication with the fluid reservoir. The drug delivery reservoir includes an adaptor disposed external to the drug delivery reservoir housing and coupled to a proximal end of the dip tube.
The present disclosure relates to anti-CD79b antibodies and anti-CD79b antibody drug conjugates (anti-CD79b ADCs) comprising thereof, where the anti-CD79b ADCs further comprise a topoisomerase 1 inhibitor (Top1i) drug as a payload. The present disclosure further relates to methods of using such anti-CD79b ADCs for treating B-cell non-Hodgkin lymphoma (B-NHL), diffuse large B cell lymphoma (DLBCL), Burkitt's lymphoma, mantle cell lymphoma, and follicular lymphoma.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates, in part, to risankizumab compositions having a reduced level of hitchhiker protein PLA2, Poloxamer 188, and/or decreased immunogenicity.
(1) Physician incentive award program to promote physician loyalty which provides incentives and rewards related to purchases of aesthetic products; administration of loyalty rewards program in the field of aesthetic products; administration of physician loyalty programs; operation of physician incentive, award and loyalty programs; administration of sales promotion incentive programs; loyalty program services namely the operation of a program involving discounts, incentives or points for the purchase of selected goods or services; providing information on the administration of a physician loyalty program via a website
(1) Physician incentive award program to promote physician loyalty which provides incentives and rewards related to purchases of aesthetic products; administration of loyalty rewards program in the field of aesthetic products; administration of physician loyalty programs; operation of physician incentive, award and loyalty programs; administration of sales promotion incentive programs; loyalty program services namely the operation of a program involving discounts, incentives or points for the purchase of selected goods or services; providing information on the administration of a physician loyalty program via a website.
(1) Physician incentive award program to promote physician loyalty which provides incentives and rewards related to purchases of aesthetic products; administration of loyalty rewards program in the field of aesthetic products; administration of physician loyalty programs; operation of physician incentive, award and loyalty programs; administration of sales promotion incentive programs; loyalty program services namely the operation of a program involving discounts, incentives or points for the purchase of selected goods or services; providing information on the administration of a physician loyalty program via a website.
(1) Physician incentive award program to promote physician loyalty which provides incentives and rewards related to purchases of aesthetic products; administration of loyalty rewards program in the field of aesthetic products; administration of physician loyalty programs; operation of physician incentive, award and loyalty programs; administration of sales promotion incentive programs; loyalty program services namely the operation of a program involving discounts, incentives or points for the purchase of selected goods or services; providing information on the administration of a physician loyalty program via a website.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Promoting public awareness of immunology, autoimmune diseases, dermatology, rheumatology and treatments thereof Providing a website featuring non-downloadable publications in the nature of brochures, articles, and newsletters in the field of health; Educational services, namely, training in the field of immunology, autoimmune diseases, dermatology, rheumatology and treatments thereof Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing scientific research information concerning clinical study results and clinical study data by means of interactive websites; providing scientific information in the field of immunology, autoimmune diseases, dermatology, rheumatology and treatments thereof via the internet, digital media and data banks
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Promoting public awareness of immunology, autoimmune diseases, dermatology, rheumatology and treatments thereof Providing a website featuring non-downloadable publications in the nature of brochures, articles, and newsletters in the field of health; Educational services, namely, training in the field of immunology, autoimmune diseases, dermatology, rheumatology and treatments thereof Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing scientific information in the field of immunology, auto-immune diseases, dermatology, rheumatology and treatments thereof via the internet, digital media and data banks; Providing scientific research information concerning clinical study results and clinical study data by means of interactive websites
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals for human use, namely, pharmaceutical preparations for treatment of cancer; pharmaceuticals for human use, namely, pharmaceutical preparations for treatment of oncological diseases, disorders, and conditions.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceuticals for human use, namely, pharmaceutical preparations for treatment of cancer; pharmaceuticals for human use, namely, pharmaceutical preparations for treatment of oncological diseases, disorders, and conditions
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals for human use, namely, pharmaceutical preparations for treatment of cancer; pharmaceuticals for human use, namely, pharmaceutical preparations for treatment of oncological diseases, disorders, and conditions
A wearable automatic injection device is provided for administering a final medicament to a patient. The wearable automatic injection device comprises a housing, an injection assembly for injecting the patient with the final medicament, a container holding a bulk intermediate medicament and a diluent to be mixed to form the medicament, and a mixing mechanism for mixing the bulk intermediate medicament and the diluent in the container to form the final medicament prior. A system for administering a final medicament to a patient is also provided. The system comprises a container, a mixing mechanism for mixing a bulk intermediate medicament and a diluent in the container to form the final medicament, and a wearable automatic injection device configured to receive the container.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Promoting public awareness of immunology, autoimmune diseases, dermatology and related treatments thereof Providing a website featuring non-downloadable publications in the nature of brochures, articles, and newsletters in the field of health; Educational services, namely, training in the field of immunology, autoimmune diseases, dermatology and treatments thereof Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing scientific information in the field of immunology, autoimmune diseases, dermatology and treatments thereof via the internet, digital media and data banks; Providing scientific research information concerning clinical study results and clinical study data by means of interactive websites Providing medical information, namely, information regarding medical conditions, treatments and products to patients and healthcare professionals in the field of immunology, autoimmune diseases, and dermatology; medical consultation, namely, providing advice to healthcare professionals regarding medical conditions and treatment in the field of immunology, autoimmune diseases, and dermatology
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Promoting public awareness of immunology, autoimmune diseases, dermatology and related treatments thereof Providing a website featuring non-downloadable publications in the nature of brochures, articles, and newsletters in the field of health; Educational services, namely, training in the field of immunology, autoimmune diseases, dermatology and treatments thereof Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing scientific information in the field of immunology, autoimmune diseases, dermatology and treatments thereof via the internet, digital media and data banks; Providing scientific research information concerning clinical study results and clinical study data by means of interactive websites Providing medical information, namely, information regarding medical conditions, treatments and products to patients and healthcare professionals in the field of immunology, autoimmune diseases, and dermatology; medical consultation, namely, providing advice to healthcare professionals regarding medical conditions and treatment in the field of immunology, autoimmune diseases, and dermatology
Provided herein is a process for the preparation of an apoptosis-inducing agent, and chemical intermediates thereof. Also provided herein are novel chemical intermediates related to the process provided herein.
C07C 315/02 - Preparation of sulfonesPreparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals for human use, namely, pharmaceutical preparations for treatment of cancer; pharmaceuticals for human use, namely, pharmaceutical preparations for treatment of oncological diseases, disorders, and conditions.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceuticals for human use, namely, pharmaceutical preparations for treatment of cancer; pharmaceuticals for human use, namely, pharmaceutical preparations for treatment of oncological diseases, disorders, and conditions
92.
ENZYME COMPOSITIONS WITH REDUCED VIRAL AND MICROBIAL CONTAMINATION
The present invention pertains to an enzyme preparation obtained from e-beam irradiated animal tissue, such as porcine pancreas. The present invention also pertains to methods for making such enzyme preparations, pharmaceutical compositions comprising such enzymes preparations, and methods for using such pharmaceutical compositions and enzyme preparations.
Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
The present disclosure provides for compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit the activity of TIPARP, wherein the variables have any of the values defined in the specification.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
C07C 235/02 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
The present disclosure provides for compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit the activity of TIPARP, wherein the variables have any of the values defined in the specification.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Provided herein are compounds of Formula (I), compounds of Formula (II) and pharmaceutically acceptable salts thereof, useful as LPAR1 inhibitors, and pharmaceutical compositions comprising the same. Also provided are methods of treating or preventing a disease or condition comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) or a compound of Formula (II).
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
The present disclosure relates, in part, to risankizumab compositions having a reduced level of hitchhiker protein PLA2, Poloxamer 188, and/or decreased immunogenicity.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
